[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:head-and-neck-squamous-cell-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":304,"states":340},"Head and Neck Squamous Cell Carcinoma",228,203,[8,16,23,29,35,42,48,54,60,66,72,79,85,91,97,103,109,115,121,126,132,138,144,149,155,161,167,173,179,185,191,197,203,209,215,220,227,232,237,243,249,254,260,266,272,278,283,288,293,299],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04915183","Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer",[12],"Phase 2","RECRUITING","2026-08-26T02:19:29.119921Z","2026-07-05T05:32:16.796673Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06496178","A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)",[20],"Phase 3","2026-08-26T02:15:28.524219Z","2026-07-05T05:32:16.756449Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07094685","Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer",[12],"2026-08-26T02:16:05.813655Z","2026-07-05T05:32:16.734917Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06959082","Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer",[12],"2026-08-26T02:18:41.390601Z","2026-07-05T05:32:16.721613Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT07219212","A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma",[39],"Phase 1","2026-08-26T02:17:34.833510Z","2026-07-05T05:32:16.664101Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05420948","A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer",[12],"2026-08-26T02:15:15.642947Z","2026-05-13T02:55:06.348673Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT04722523","A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer",[39],"2026-08-26T02:18:02.701182Z","2026-05-05T02:47:14.270912Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT07276399","A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent\u002FMetastatic Head and Neck Cancer",[20],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:29.738036Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06239220","PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC",[12],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:29.726685Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT04892173","JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC",[20],"2026-08-26T02:18:32.765187Z","2026-05-05T02:43:29.722667Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":77,"content_modified":78},"NCT06096038","Autologous CAR-T Cells Targeting CSPG4 in Relapsed\u002FRefractory HNSCC",[76],"Phase 1\u002FPhase 2","2026-08-26T02:15:56.561131Z","2026-05-05T02:43:29.646965Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06597565","A Phase II Study of ACR-368 and Low Dose Gemcitabine in R\u002FM HNSCC",[12],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:29.645303Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05977907","Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).",[12],"2026-08-26T02:18:53.782384Z","2026-05-05T02:43:29.509117Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05913388","GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma",[12],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:29.508149Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06693323","Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W\u002F SOC Tx for HPV+ Pts W\u002F HNSCC",[12],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:29.382550Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06385080","A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer",[76],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:29.372476Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT05901545","Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer",[39],"2026-08-26T02:17:52.450442Z","2026-05-05T02:43:29.196962Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06607406","Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery",[],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:29.183951Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":101,"content_modified":125},"NCT05031910","Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality",[],"2026-05-05T02:43:29.161530Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT06769698","A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[12],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:29.044914Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT05889091","A Study of the Use of Fat Flap Reconstruction to Reduce Neck Injury After Cancer Treatment",[],"2026-08-26T02:15:30.699880Z","2026-05-05T02:43:29.018597Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT06137274","Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC",[12],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:29.016556Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":89,"content_modified":148},"NCT06912087","Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC",[39],"2026-05-05T02:43:29.015140Z",{"nct_id":150,"title":151,"phases":152,"status":13,"updated_at":153,"content_modified":154},"NCT06064877","A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R\u002FM) HPV Negative Head and Neck Squamous Cell Carcinoma",[20],"2026-08-26T02:15:42.447052Z","2026-05-05T02:43:28.966166Z",{"nct_id":156,"title":157,"phases":158,"status":13,"updated_at":159,"content_modified":160},"NCT04988074","Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w\u002FHPV H&N Ca",[12],"2026-08-26T02:18:44.395098Z","2026-05-05T02:43:28.875169Z",{"nct_id":162,"title":163,"phases":164,"status":13,"updated_at":165,"content_modified":166},"NCT06161545","Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma",[12],"2026-08-26T02:19:28.327680Z","2026-05-05T02:43:28.822240Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":171,"content_modified":172},"NCT03480971","Treatment of Radiation and Cisplatin Induced Toxicities with Tempol",[12],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.736375Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":177,"content_modified":178},"NCT07213934","Phase I\u002F II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma",[76],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.733927Z",{"nct_id":180,"title":181,"phases":182,"status":13,"updated_at":183,"content_modified":184},"NCT02128906","Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design",[12],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:28.675648Z",{"nct_id":186,"title":187,"phases":188,"status":13,"updated_at":189,"content_modified":190},"NCT06997094","Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer",[39],"2026-08-26T02:16:27.227548Z","2026-05-05T02:43:28.650454Z",{"nct_id":192,"title":193,"phases":194,"status":13,"updated_at":195,"content_modified":196},"NCT06005324","Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer",[39],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:28.558830Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT06736379","Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer",[39],"2026-08-26T02:16:16.169331Z","2026-05-05T02:43:28.548931Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":207,"content_modified":208},"NCT06998069","Head and Neck Cancer Study Project in the Geriatric Population",[20],"2026-08-26T02:19:17.380174Z","2026-05-05T02:43:28.531850Z",{"nct_id":210,"title":211,"phases":212,"status":13,"updated_at":213,"content_modified":214},"NCT04754321","Combining Immunotherapy Salvage Surgery & IORT Tx Persistent\u002FRecurrent Head & Neck Cancer",[39],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:28.496351Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":165,"content_modified":219},"NCT05838729","Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer",[76],"2026-05-05T02:43:28.182577Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":225,"content_modified":226},"NCT06788990","FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC",[224],"Phase 2\u002FPhase 3","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:28.180688Z",{"nct_id":228,"title":229,"phases":230,"status":13,"updated_at":33,"content_modified":231},"NCT05136196","BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study",[12],"2026-05-05T02:43:28.127738Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":213,"content_modified":236},"NCT06636734","Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial",[12],"2026-05-05T02:43:28.112845Z",{"nct_id":238,"title":239,"phases":240,"status":13,"updated_at":241,"content_modified":242},"NCT05952934","Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence",[12],"2026-08-26T02:18:49.989941Z","2026-05-05T02:43:28.023213Z",{"nct_id":244,"title":245,"phases":246,"status":13,"updated_at":247,"content_modified":248},"NCT04534205","A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1",[224],"2026-08-26T02:17:51.502023Z","2026-05-05T02:43:28.001380Z",{"nct_id":250,"title":251,"phases":252,"status":13,"updated_at":136,"content_modified":253},"NCT06525220","A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)",[20],"2026-05-05T02:43:27.989461Z",{"nct_id":255,"title":256,"phases":257,"status":13,"updated_at":258,"content_modified":259},"NCT05674396","3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial",[12],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:27.963916Z",{"nct_id":261,"title":262,"phases":263,"status":13,"updated_at":264,"content_modified":265},"NCT04966481","Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1\u002FL1 Inhibitor",[20],"2026-08-26T02:18:16.220328Z","2026-05-05T02:43:27.959921Z",{"nct_id":267,"title":268,"phases":269,"status":13,"updated_at":270,"content_modified":271},"NCT07063212","A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)",[12],"2026-08-26T02:17:10.213717Z","2026-05-05T02:43:27.834863Z",{"nct_id":273,"title":274,"phases":275,"status":13,"updated_at":276,"content_modified":277},"NCT03708224","Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck",[12],"2026-08-03T02:34:16.012157Z","2026-05-05T02:43:27.804407Z",{"nct_id":279,"title":280,"phases":281,"status":13,"updated_at":27,"content_modified":282},"NCT07465276","Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC",[12],"2026-05-05T02:43:27.642456Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":130,"content_modified":287},"NCT06211335","Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma",[39],"2026-05-05T02:43:27.638081Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":247,"content_modified":292},"NCT06052839","Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent\u002FMetastatic HNSCC",[12],"2026-05-05T02:43:27.629500Z",{"nct_id":294,"title":295,"phases":296,"status":13,"updated_at":297,"content_modified":298},"NCT06868433","TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and\u002For Metastatic Head and Neck Squamous Cell Cancer",[39],"2026-08-26T02:17:36.611194Z","2026-05-05T02:43:27.603586Z",{"nct_id":300,"title":301,"phases":302,"status":13,"updated_at":40,"content_modified":303},"NCT07172256","CUE-101with Pembrolizumab for LA-HPV+HNSCCs",[12],"2026-05-05T02:43:27.601527Z",[305,309,313,317,321,325,329,333,336],{"biomarker":306,"count":307,"slug":308},"Programmed Cell Death 1 Ligand 1",31,"programmed-cell-death-1-ligand-1",{"biomarker":310,"count":311,"slug":312},"HPV",15,"hpv",{"biomarker":314,"count":315,"slug":316},"MSI1 Gene",14,"msi1-gene",{"biomarker":318,"count":319,"slug":320},"CDKN2A wt Allele",10,"cdkn2a-wt-allele",{"biomarker":322,"count":323,"slug":324},"Soluble Epidermal Growth Factor Receptor",9,"soluble-epidermal-growth-factor-receptor",{"biomarker":326,"count":327,"slug":328},"MRC1 wt Allele",7,"mrc1-wt-allele",{"biomarker":330,"count":331,"slug":332},"BRAF Gene",4,"braf-gene",{"biomarker":334,"count":331,"slug":335},"TPM2 wt Allele","tpm2-wt-allele",{"biomarker":337,"count":338,"slug":339},"PIK3CA Gene",3,"pik3ca-gene",[341,345,349,353,357,361,365,369,373,377,381,385,388,392,396,400,404,407,411,414,418,421,425,429],{"state":342,"count":343,"slug":344},"California",98,"california",{"state":346,"count":347,"slug":348},"Texas",97,"texas",{"state":350,"count":351,"slug":352},"Florida",76,"florida",{"state":354,"count":355,"slug":356},"New York",74,"new-york",{"state":358,"count":359,"slug":360},"Virginia",61,"virginia",{"state":362,"count":363,"slug":364},"Tennessee",59,"tennessee",{"state":366,"count":367,"slug":368},"Ohio",58,"ohio",{"state":370,"count":371,"slug":372},"Pennsylvania",55,"pennsylvania",{"state":374,"count":375,"slug":376},"Massachusetts",53,"massachusetts",{"state":378,"count":379,"slug":380},"Michigan",49,"michigan",{"state":382,"count":383,"slug":384},"Illinois",46,"illinois",{"state":386,"count":383,"slug":387},"North Carolina","north-carolina",{"state":389,"count":390,"slug":391},"Missouri",43,"missouri",{"state":393,"count":394,"slug":395},"New Jersey",35,"new-jersey",{"state":397,"count":398,"slug":399},"Georgia",33,"georgia",{"state":401,"count":402,"slug":403},"Colorado",32,"colorado",{"state":405,"count":307,"slug":406},"Washington","washington",{"state":408,"count":409,"slug":410},"Connecticut",30,"connecticut",{"state":412,"count":409,"slug":413},"Minnesota","minnesota",{"state":415,"count":416,"slug":417},"Maryland",29,"maryland",{"state":419,"count":416,"slug":420},"Utah","utah",{"state":422,"count":423,"slug":424},"Arizona",28,"arizona",{"state":426,"count":427,"slug":428},"Oregon",27,"oregon",{"state":430,"count":431,"slug":432},"Kentucky",25,"kentucky"]